LisaAKottschadeNP

PubMed

• 74 citations
  Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
  Narjust Duma, Azzouqa Abdel‐Ghani, Siddhartha Yadav, Katherine P. Hoversten, Clay T Reed, Andrea N. Sitek, Elizabeth Ann L. Enninga, Jonas Paludo, Jesus Vera Aguilera,...> ;The Oncologist. 2019 Apr 29
• 15 citations
  The Future of Immunotherapy in the Treatment of Cancer.
  Lisa A. Kottschade> ;Seminars in Oncology Nursing. 2019 Aug 30
• 90 citations
  Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
  Michael D. Richter, Cynthia S. Crowson, Lisa A. Kottschade, Heidi D. Finnes, Svetomir N. Markovic, Uma Thanarajasingam> ;Arthritis & Rheumatology. 2019 Mar 1
• 4 citations
  Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.
  Jesus Vera, Jonas Paludo, Lisa A. Kottschade, Jessica Brandt, Yiyi Yan, Matthew S. Block, Robert R. McWilliams, Roxana S. Dronca, Charles L. Loprinzi, Axel Grothey, Sv...> ;Supportive Care in Cancer. 2019 Feb 14
• 12 citations
  Neoadjuvant systemic therapy for regionally advanced melanoma
  James W. Jakub, Jennifer M. Racz, Tina J. Hieken, Lisa A. Kottschade, Svetomir N. Markovic, Yiyi Yan, Matthew S. Block> ;Journal of Surgical Oncology. 2018 May 1
• 32 citations
  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
  Lisa A. Kottschade> ;Current Oncology Reports. 2018 Mar 6
• Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience
  Lisa A Kottschade, Svetomir N Markovic, Michael D Richter, Olga Pinkston, Uma Thanarajasingam> ;Arthritis & Rheumatology.
• 16 citations
  NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
  Robert R. McWilliams, Jacob B. Allred, Jessica A. Slostad, Rajini Katipamula, Roxana S. Dronca, Kandelaria M. Rumilla, Lori A. Erickson, Alan H. Bryce, Richard W. Jose...> ;Cancer. 2018 Feb 1
• 163 citations
  Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
  Danae A. Delivanis, Michael P. Gustafson, Svetlana Bornschlegl, Michele M Merten, Lisa A. Kottschade, Sarah G. Withers, Allan B. Dietz, Mabel Ryder> ;The Journal of Clinical Endocrinology and Metabolism. 2017 Aug 1
• 23 citations
  Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
  Roberto A. Leon-Ferre, Lisa A. Kottschade, Matthew S. Block, Robert R. McWilliams, Roxana S. Dronca, Edward T. Creagan, Jacob B. Allred, Val J. Lowe, Svetomir N. Markovic> ;Melanoma Research. 2017 Aug 1
• 131 citations
  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
  Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, Lisa A. Kottschade, Andrea Forschner, Ralf Gutzmer, Max Schlaak, Lucie Heinzerling, Angela M. Krackhardt, Carmen Loquai, Sv...> ;European Journal of Cancer. 2017 Apr 1
• 15 citations
  Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
  Alexey A. Leontovich, Roxana S. Dronca, Wendy K. Nevala, Michael A. Thompson, Lisa A. Kottschade, Leonid V. Ivanov, Svetomir N. Markovic> ;Melanoma Research. 2017 Feb 1
• 38 citations
  Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
  Jarrett J. Failing, Heidi D. Finnes, Lisa A. Kottschade, Jacob B. Allred, Svetomir N. Markovic> ;Melanoma Research. 2016 Dec 1
• 21 citations
  A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
  Lisa A. Kottschade, Adam K. Brys, Tobias Peikert, Mabel Ryder, Laura E. Raffals, Jerry D. Brewer, Paul J. Mosca, Svetomir N. Markovic> ;Melanoma Research. 2016 Oct 1
• 59 citations
  T cell Bim levels reflect responses to anti–PD-1 cancer therapy
  Roxana S. Dronca, Xin Liu, Susan M. Harrington, Lingling Chen, Siyu Cao, Lisa A. Kottschade, Robert R. McWilliams, Matthew S. Block, Wendy K. Nevala, Michael A. Thomps...> ;JCI Insight. 2016 May 5
• 13 citations
  Recurrence and Survival Outcomes after Percutaneous Thermal Ablation of Oligometastatic Melanoma
  Mariah L. White, Thomas D. Atwell, A. Nicholas Kurup, Grant D. Schmit, Rickey E. Carter, Jennifer R. Geske, Lisa A. Kottschade, Jose S. Pulido, Matthew S. Block, James...> ;Mayo Clinic Proceedings. 2016 Mar 1
• 26 citations
  Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance)
  Lisa A. Kottschade, Paul J. Novotny, Alan P. Lyss, Miroslaw Mazurczak, Charles L. Loprinzi, Debra L. Barton> ;Supportive Care in Cancer. 2016 Jan 15
• 27 citations
  The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma.
  Nicole M. Rochet, Lisa A. Kottschade, Travis E. Grotz, Luis F. Porrata, Svetomir N. Markovic> ;American Journal of Clinical Oncology. 2015 Jun 1
• 25 citations
  Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
  Tulasi Gummadi, Ben Y. Zhang, Sara Valpione, Chul Kim, Lisa A. Kottschade, Rajendar K. Mittapalli, Vanna Chiarion-Sileni, Jacopo Pigozzo, William F. Elmquist, Arkadius...> ;Melanoma Research. 2015 Feb 1
• 20 citations
  Rare presentations of primary melanoma and special populations: a systematic review.
  Lisa A. Kottschade, Travis E. Grotz, Roxana S. Dronca, Diva R. Salomao, Jose S. Pulido, Nabil Wasif, James W. Jakub, Sanjay P. Bagaria, Riten Kumar, Judith S. Kaur, Sh...> ;American Journal of Clinical Oncology. 2014 Dec 1
• 13 citations
  Phase III double‐blind, placebo‐controlled study of gabapentin for the prevention of delayed chemotherapy‐induced nausea and vomiting in patients receiving highly emet...
  Debra L. Barton, Gita Thanarajasingam, Jeff A. Sloan, Brent Diekmann, Jyotsna Fuloria, Lisa A. Kottschade, Alan P. Lyss, Anthony J. Jaslowski, Miroslaw Mazurczak, Scot...> ;Cancer. 2014 Nov 15
• 22 citations
  Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy.
  Ellen M. Lavoie Smith, Grace Campbell, Cindy Tofthagen, Lisa A. Kottschade, Mary Collins, Charlene Warton, Bidisha Ghosh, David L. Ronis, Gail Mallory, Constance Visovsky> ;Oncology Nursing Forum. 2014 Oct 29
• 23 citations
  Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
  Travis E. Grotz, Lisa A. Kottschade, Emily S. Pavey, Svetomir N. Markovic, James W. Jakub> ;American Journal of Clinical Oncology. 2014 Oct 1
• 2 citations
  NURSING'S PRESENCE IN THE CHANGING COOPERATIVE GROUP SETTING
  Lisa A. Kottschade, Jennifer M. Bell, Kathy Klinger, Ellen M. Lavoie Smith> ;Seminars in Oncology Nursing. 2014 Feb 1
• 36 citations
  The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9
  Debra L. Barton, Kelli N. Burger, Paul J. Novotny, Tom R. Fitch, Sadhna Kohli, Gamini S. Soori, Mary B. Wilwerding, Jeff A. Sloan, Lisa A. Kottschade, Kendrith M. Rowl...> ;Supportive Care in Cancer. 2013 Apr 1
• Join now to see all